Research and development is long, expensive, and risky.
With so much invested, failure is not an option.

3D has a proven preparation process for communicating and negotiating with FDA AND EMEA regulators at every stage of product development.  

3D ACT™ (Analysis, Content Development, Testing) has demonstrated success with drugs, devices, and challenging regulatory issues.

From key regulatory discussions to FDA advisory committee meetings, 3D’s team of experts works side-by-side with your researchers, investigators, doctors, advocacy groups, and executives to anticipate regulatory scrutiny, influence regulators, and build to "yes".

• 3D ACT™ Process for FDA Advisory Committee
   Meetings and CHMP Oral Hearings